

CIAS1 and NOD2 Genes in Adult-onset Still's Disease

To the Editor:

We read with interest the article by Eriksson, *et al*¹ presenting a patient diagnosed with adult-onset Still's disease (AOSD) and successfully treated with interleukin-1 β (IL-1 β) blockade, in whom the heterozygous germline p.R260W *NLRP3* mutation was finally detected. AOSD is a systemic inflammatory disease characterized by fever, rash, articular involvement, lymphadenopathy, hepatosplenomegaly, and serositis². Its cause remains unknown, but it is now considered an autoinflammatory disease on the basis of the absence of autoantibodies or autoantigen-specific T cells and the central role of IL-1 β in its pathogenesis^{3,4}.

AOSD differential diagnosis should include the group of hereditary autoinflammatory diseases, especially the dominantly inherited cryopyrin-associated periodic syndromes (CAPS) and Blau syndrome (BS). The CAPS syndromes are caused by heterozygous gain-of-function mutations in the *NLRP3* gene and share several clinical features with AOSD such as fever, cutaneous and musculoskeletal involvement, and serositis⁵. These similar features were highlighted by Bywaters in the first report of AOSD, in which he also included the Muckle-Wells syndrome (an inflammatory disease currently included among the CAPS syndromes) in the differential diagnosis of AOSD⁶. BS is a different autoinflammatory disease associated with heterozygous gain-of-function *NOD2* mutations and characterized like AOSD by fever, chronic arthritis, and uveitis⁵.

Because AOSD, CAPS, and BS can share some clinical features, we evaluated the potential presence of mutations in the *NLRP3* and *NOD2* genes in a cohort of 18 patients with AOSD from 2 hospitals in Catalonia, Spain. All the patients fulfilled the Yamaguchi criteria, and informed consent was obtained from each participant. The study protocol was approved by the ethics committee. Genomic DNA was extracted from whole blood using the Roche MagNAPure Compact (Roche Diagnostics). Exon 3 of the *NLRP3* gene (GenBank NM 001243133.1) and exon 4 of the *NOD2* gene (GenBank NM 022162.1) were amplified by polymerase chain reaction. Bidirectional fluorescence sequencing was performed using an ABI BigDye Terminator version 3.1 Cycle Sequencing kit and run on a 3730XL DNA Analyzer. As a control population, the European samples from the 1000 Genome Project ($n = 379$) were used. Differences in frequencies of alleles between patients with AOSD and controls were analyzed using the chi-square method, Fisher's exact test, and logistic regression with Statistical Analysis Software (SAS).

Most patients with AOSD showed no structural mutations in the *NLRP3* or the *NOD2* gene. However, different nonsynonymous gene variants were detected in both genes (Table 1). Two different patients carried variants in the *NLRP3* gene. One patient carried the heterozygous

p.V198M variant (rs121908147), currently considered as a low-penetrance mutation⁷, and another patient carried the p.Q703K (rs35829419) variant, which is a polymorphism of the *NLRP3* gene with variable frequencies in the different analyzed populations⁸. Two patients carried the heterozygous p.R702W *NOD2* variant (rs206684). This is a common *NOD2* polymorphism described as a risk factor for Crohn disease⁹, but the 2 AOSD patients with this *NOD2* variant did not exhibit any symptom suggestive of inflammatory bowel disease. Another patient carried the heterozygous p.R791Q *NOD2* variant (rs104895464), which has been reported in a patient with spondyloarthritis and is currently considered as a variant of uncertain significance¹⁰.

The case presented by Eriksson, *et al* is a good example of the clinical similarities between AOSD and hereditary autoinflammatory diseases and confirms our opinion that, because the diagnosis of AOSD is one of exclusion, clinicians should rule out these inherited diseases in the AOSD differential diagnosis¹. Despite the absence of *NLRP3* or *NOD2* mutations in our series, we recommend the genetic analysis when available for this objective. Moreover, the presence of a mutation in a gene involved in IL-1 β processing could explain the good response to IL-1 β blockade.

EMMA GARCIA-MELCHOR, MD, Department of Immunology, Hospital Clínic Barcelona; DOLORS GRADOS, MD, Department of Rheumatology, Hospital Universitari Germans Trias i Pujol; EVA GONZÁLEZ-ROCA, MD, PhD, Department of Immunology, Hospital Clínic Barcelona; JUAN I. AROSTEGUI, MD, PhD, Department of Immunology, Hospital Clínic Barcelona; JORDI YAGUE, MD, PhD, Department of Immunology, Hospital Clínic Barcelona; FRANCISCO JAVIER NARVÁEZ, MD, PhD, Department of Rheumatology, Hospital de Bellvitge; ALEJANDRO OLIVE, MD, PhD, Department of Rheumatology, Hospital Germans Trias i Pujol, Barcelona, Spain. Address correspondence to Dr. Garcia-Melchor. E-mail: emmitagm@gmail.com

REFERENCES

- Eriksson P, Jacobs C, Söderkvist P. A patient with a phenotype of adult-onset still disease, but a genotype typical of cryopyrin-associated periodic fever syndrome. *J Rheumatol* 2013;40:1632-3.
- Fautrel B. Adult-onset Still disease. *Best Pract Res Clin Rheumatol* 2008;22:773-92.
- Galon J, Aksentijevich I, McDermott MF, O'Shea JJ, Kastner DL. TNFRSF1A mutations and autoinflammatory syndromes. *Curr Opin Immunol* 2000;12:479-86.
- Rossi-Semerano L, Koné-Paut I. Is Still's disease an autoinflammatory syndrome? *Int J Inflam* 2012;2012:480373.

Table 1. Allelic frequencies in patients with AOSD and healthy controls. Differences (p) were calculated with chi-square or Fisher's exact test.

Protein Name	Sequence Change	rs No.	MAF AOSD	MAF Controls	p	OR (95% CI)
NLRP3						
p.Ala242Ala	c.726G > A	rs3806268	0.472	0.453	0.8164	1.0826 (0.5541–2.1151)
p.Thr219Thr	c.657C > T	rs7525979	0.055	0.059	1.0000	0.9320 (0.2170–4.0035)
p.Ser434Ser	c.1302C > T	rs34298354	0.083	0.112	0.7880	0.7198 (0.2161–2.3975)
p.Arg260Arg	c.780G > A	rs4925543	0.055	0.044	0.6693	1.2923 (0.2977–5.6102)
p.Gln703Lys	c.2107C > A	rs35829419	0.027	0.041	1.0000	0.6700 (0.0889–5.0510)
p.Pro340Pro	c.1020C > T	rs41311573	0.027	0.011	0.3428	2.6786 (0.3259–22.0120)
p.Val198Met	c.592G > A	rs121908147	0.027	0.013	0.4017	2.1371 (0.2661–17.1647)
NOD2						
p.Pro268Ser	c.802C > T	rs2066842	0.333	0.243	0.2181	1.5598 (0.7649–3.1807)
p.Arg459Arg	c.1377C > T	rs2066843	0.333	0.243	0.2181	1.5598 (0.7649–3.1807)
p.Arg587Arg	c.1761T > G	rs1861759	0.305	0.423	0.1610	0.5990 (0.2905–1.2351)
p.Arg702Trp	c.2104C > T	rs2066844	0.055	0.051	0.7085	1.0845 (0.2513–4.6792)
p.Arg791Gln	c.2372G > A	rs104895464	0.027	0.001	0.0887	21.6286 (1.3252–352.9972)*

* $p < 0.05$. AOSD: Adult-onset Still's disease; MAF: minor allele frequency.

5. Hull KM, Shoham N, Chae JJ, Aksentjevich I, Kastner DL. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. *Curr Opin Rheumatol* 2003;15:61-9.
6. Bywaters EG. Still's disease in the adult. *Ann Rheum Dis* 1971;30:121-33.
7. Arostegui JI, Aldea A, Modesto C, Rua MJ, Argüelles F, González-Enseñat MA, et al. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. *Arthritis Rheum* 2004;50:4045-50.
8. Aksentjevich I, D Putnam C, Remmers EF, Mueller JL, Le J, Kolodner RD, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. *Arthritis Rheum* 2007;56:1273-85.
9. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature* 2001;411:599-603.
10. Miceli-Richard C, Zouali H, Lesage S, Thomas G, Hugot JP, Said-Nahal R, et al. CARD15/NOD2 analyses in spondylarthropathy. *Arthritis Rheum* 2002;46:1405-6.

J Rheumatol 2014;41:7; doi:10.3899/jrheum.131563